We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > G1 Therapeutics

News List

G1 Therapeutics and Genor Biopharma sign agreement for Lerociclib expresspharma
June 24, 2020
As per the exclusive license agreement, Genor to lead clinical development, regulatory submissions and commercialisation of lerociclib in Asia-Pacific.
Quantum Leap Healthcare, G1 Therapeutics Announce Trilaciclib Evaluation americanpharmaceuticalreview
January 16, 2020
Quantum Leap Healthcare Collaborative™ and G1 Therapeutics announced a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy, in a new randomized ...
G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel firstwordpharma
July 10, 2018
G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and
G1 Therapeutics Unveils Positive Mid-Stage Data for Myelopreservation in SCLC Patients biospace
March 06, 2018
A mid-stage program aimed at treating myelosuppression in lung cancer patients undergoing chemotherapy is yielding positive results